May disrupt tumor pH regulation—by inhibiting vacuolar-type H+-ATPases in cancer cells—which can alter drug uptake/resistance and potentially sensitize tumors (e.g., gliomas) [160,161]. Here, ATP6V1A is linked to cancer.